Related references
Note: Only part of the references are listed.Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non-Small Cell Lung Cancer Patients
Irene Yam et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases
Hye-Suk Han et al.
CLINICAL LUNG CANCER (2011)
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
Marie Brevet et al.
LUNG CANCER (2011)
Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
Hideharu Kimura et al.
CLINICAL CANCER RESEARCH (2006)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
